|
Final
Segment #1: |
 |
'Executive
Decision'
'CEO
Interview'
Interview
with
David Snow,
CEO
Medco Health |
 |
|
Monday,
February 2, 2009 |
|
|
 |
 |
|
|
Jim's
rating on
this stock |
STOCK
SYMBOL |
Closing
price that
day |
Full Company Name |
|
 |
MHS |
45.61 |
MedcoHealth Solutions Inc.
(MHS)
|
|
Jim:
I always tell people
that you have got to
read the papers… you
have got to read the
local papers… you
always have to be
cognizant… here is
one I am reading in
the Boston Globe
today… a battle over
mail order drugs…
saving and
effectiveness
debated… okay, so
what is that to do…
you are sitting
there and thinking
what is the budget
going to look like…
no… it is talking
about how Medco…
that is right...
MedcoHealth Solutions Inc.
(MHS)…
which has been one
of our absolute
favorite stocks on
this show… could be
a gigantic winner if
Medicare simply
gives them the mail
service contract… it
would save the tax
payer… it would save
the government… it
could save you…
let’s bring on one
of the best CEO’s in
the healthcare
business… David
Snow, Medco Health
Solutions chairman
and CEO…
|
|
Continued below...
|
|
|
|
|
|
|
|
|
|
Monday,
October 22, 2008
(Cont'd from
above)...
▼ ▼
▼ ▼
▼
Start of
Interview
with
David Snow,
CEO...
Jim:
David how are you?
David:
I am doing well,
Jim, how about you?
Jim:
Okay, David set the
scene here… we know
that the government
is strapped… we know
that there isn’t
enough money for
healthcare… it seems
like there is a
simple solution to
lowering the cost
right now, and it
involves Medco, tell
us about it.
David:
Sure, well first of
all you save 10%
across the board
when you buy your
drugs through mail
vs. a retail
setting, and that is
important. But that
is not going to save
healthcare. What is
really powerful is
that if you manage
chronic and complex
disease with
specialist
pharmacists tied to
protocol, you can
get a $350B of waste
in this country tied
to inappropriate
management of
chronic and complex
disease. Most
important, is the
clients, but there
are other issues as
well. So having a
clinical setting
that manages at the
disease level in a
superior way, can
save our country an
awful lot of money.
Jim:
Alright, David, I
would tell you that
my local pharmacist,
who could be more
accurate than my
local pharmacist?
David:
Here is the
challenge, Jim, at a
local pharmacy level
that pharmacist
doesn’t necessarily
know that that
patient has been do
five other
pharmacies, from 6
other doctors, it
really has to come
through a PBM -
pharmacy benefit
manager - that
information, and
then the pharmacist
has to have the time
to actually work
with that patient,
and work with that
physician, it is not
easy to do that at
the counter at a
drug store. It is
very hard.
Jim:
Is the issue here…
cause this seems
like…. I mean look…
there is no such
thing as lay ups… it
would seem to me
that there is a
political clout on
the behalf of the
pharmacist… is that
what is keeping this
from happening?
David:
Not really, I mean I
think in any
reformed effort you
have to be cognizant
that there are lots
of businesses out
there that want to
survive. And people
work very hard to
protect their
businesses. And
quite frankly, Medco
needs retail
pharmacies, they are
part of our system.
Our whole point is
that we can make it
much more efficient,
and improve patient
care for better
outcomes by wiring
healthcare,
producing and
showing physician
and retail
pharmacists the
information that
helps drive better
outcomes. In a PBM
environment, where
we control the end
to end solution, we
are doing that
today.
Jim:
Okay, one of the
things that I think
people don’t
realize… they think
big warehouse… lots
of robots… doesn’t
really have any
data… just a big
mail order house.
Talk about the
sophisticated data
that you have, and
how drug companies
are smart to tap
into it.
David:
Well, we manage the
drug benefits for
about 65 million
Americans, and here
is a fact that is
important to know.
96% of all drug
costs, 75% of all
medical costs in
this country is tied
to chronic and
complex disease.
Drugs are the first
line of defense 88%
of the time when it
comes to chronic and
complex disease. So
we have the
information on the
drugs. We know the
proper protocols
around the diseases
that where you spend
this money. And the
name of the game in
healthcare, is to
keep people that are
chronic or complex
stable so that they
don’t end up with
the awful
consequences that
result in ER visits,
in-patient hospital
visits, and really
terrible
consequences
personally.
Jim:
David, one last
question… I have
always felt that the
best way to look at
your earnings power
is to see how many
drugs are going
generic… we all know
that one of the main
reasons why big
pharma has been a
terrible place to
invest for multiple
years… is people are
looking out 2010,
11, 12 and seeing
big generics… can
you explain to our
viewers why a big
generic switch is
good for Medco?
David:
Sure, there are
about $90B worth of
branded drugs that
are expected to go
off patent between
now and 2015, the
way we manage our
business, we are
aligned with our
customers best
interest. Meaning we
make our money with
generics, we don’t
make our money on
branded drugs. So we
are very aligned
when we save our
clients significant
money. That is where
we make money.
Jim:
David Snow, chairman
and CEO of Medco
Health. Thank you
for coming on the
show.
▼ ▼
▼ ▼
▼
Jim's comments AFTER
the interview:
Alright guys look…
do you really think
that at a time when
we are spending
trillions… that we
have… don’t you
think that we have
to cut every penny…
if you think like I
do… that we have to
start using more
generics… and we got
to start saving more
money for the tax
payer… than I think
you should be
thinking to be buy
MedcoHealth Solutions Inc.
(MHS)…
which, by the way,
is one of the
reasons why it acts
so well… when this
story breaks
nationwide you will
be in ahead of it.
[verbatim recap]
[end of segment]
Read Jim's next Segment
here
▼ ▼
▼ ▼
▼
Read Jim's next Segment
here
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
|
|
|
Search for Jim's past comments about a specific
stock. Use
ticker symbol or company name in quotes
(e.g., GOOG or "Google") |
|
 |
|
|
|
|
|
|